<DOC>
	<DOCNO>NCT01308528</DOCNO>
	<brief_summary>The purpose study compare safety security efficacy sodium enoxaparin Cristália Produtos Químicos Farmaceuticos Ltda - Endocris Clexane ( Sanofi-Aventis ) prevent Venous Thromboembolism Patients With High-Risk Develop Thromboembolic Disease Undergoing Geral Abdominal Surgery .</brief_summary>
	<brief_title>Prophylactic Use Sodium Enoxaparin Venous Thromboembolism High-Risk Abdominal Surgery</brief_title>
	<detailed_description>This study requirement Anvisa add new indication off-label drug</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Enoxaparin</mesh_term>
	<criteria>Men woman age 18 year undergoing abdominal surgery general high risk develop venous thromboembolism ; Who provide consent sign consent form . Clinical evidence Venous thromboembolism ( VTE ) selection ; treatment requirement anticoagulant Low Molecular Weight Heparin , Unfracted Heparin , oral anticoagulant suspicion history coagulumpathia Heparin , enoxaparin allergy hypersensitiviy know heparin , enoxaparin , restrict thrombocytopenia and/or induce thombose heparin ou enoxaparin ( thrombocytopenia induce heparin [ TIH ] , thrombocytopenia associate heparin [ TAH ] thrombotic thrombocytopenia syndrome induce heparin [ STTIH ] Active bleeding increase enoxaparin . Previous history know intracranial hemorrhage Arteryvenous malformation suspicion know cerebral aneurism Spinal , Epidural ou lumbar puncture analgesia last 24 hour previous first dose administration enoxaparin . erosive disease digestive tract especially gastroduodenal Uncontrolled hypertension ( systolic blood pressure [ BP ] &gt; 180mmHg diastolic BP &gt; 100 mm Hg ) randomization clinical hypertensive urgency ; bacterial endocarditis heart valve prosthesis characterize severe renal insufficiency creatinine clearance &lt; 30 ml / min Intraarterial thrombolic therapy Thrombolic therapy within 24 hour . Low Molecular Weight Heparin Unfraction Heparin treatment prophylactic dose 48 hour surgery oral anticoagulant within 5 day surgery disturbance consciousness coma Less 6 month expectative time life Chemical dependency Patient anesthetic risk ASA III ASA IV morbid obesity Body Mass Index ≥ 40 Chronic use corticosteroid History allergy Unfraction Heparin , Low molecular weight heparin pork product . History severe allergic episode , systemic anaphylaxis , major urticarial disease StevenJohnson Participation another clinical study within 12 month prior inclusion Potentially fertile woman without βHCG negative harvest 48 hour operation use acceptable contraception participation study Changes security check 48 h randomization : Hemoglobin &lt; 10 mg / dL ; ALT AST ≥ 2.5 time ULN ; Platelet count &lt; 100.000/mL ; INR ≥ 1.5 ; Any condition opinion investigator , could lead increase risk patient make inappropriate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Venous Thromboembolism</keyword>
</DOC>